Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
Authors:
- Olga Maria NardoneONOlga Maria Nardone
- Giovanni MarascoGiovanni Marasco
- Loris Riccardo LopetusoLLLoris Riccardo Lopetuso
- Giammarco MocciGMGiammarco Mocci
- Luca PastorelliLPLuca Pastorelli
- Carlo PetruzzellisCPCarlo Petruzzellis
- Franco ScaldaferriFSFranco Scaldaferri
- on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI)O(on behalf of the Italian Association of Young Gastroenterologist and Endoscopist (AGGEI)
Open Access
- 2 March 2023
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 2005
Abstract
Background: Mesalazine is among the medications most prescribed by gastroenterologists, with variable and controversial use in different settings. We aimed to explore the use of mesalazine in the clinical practice of young gastroenterologists. Methods: A web-based electronic survey was distributed to all participants of the National Meeting of the Italian Young Gastroenterologist and Endoscopist Association. Results: A total of 101 participants took part in the survey, with a majority (54.4%) being aged >30 years, 63.4% of whom were trainees in academic hospitals, and 69.3% of whom were involved in the clinical management of inflammatory bowel disease (IBD). While both non-dedicated and IBD physicians generally agreed on the appropriate dose of mesalazine for mild ulcerative colitis (UC), significant differences were observed between the two groups for moderate-severe ulcerative colitis (UC). Additionally, in IBD patients who were starting immuno-modulators and/or biologics, 80% of IBD-dedicated physicians continued to prescribe mesalazine, compared to 45.2% of non-dedicated physicians (p = 0.002). Indeed, 48.4% of non-dedicated IBD physicians did not acknowledge mesalazine for colorectal cancer chemoprevention. With regards to Crohn’s disease, it is mainly used by 30.1% of IBD physicians for preventing postoperative recurrence of Crohn’s disease. Finally, 57.4% used mesalazine for symptomatic uncomplicated diverticular disease, and 84.2% did not recommend its use for irritable bowel syndrome. Conclusions: This survey showed heterogeneous behaviors in the daily use of mesalazine, mainly in the management of IBD. Educational programs and novel studies are needed to clarify its use.Keywords
Funding Information
- Ferring Pharmacheuticals
This publication has 33 references indexed in Scilit:
- Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the ColonDigestive Diseases and Sciences, 2015
- Randomised controlled trial of mesalazine in IBSGut, 2014
- Randomised clinical trial: mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - a double-blind, randomised, placebo-controlled studyAlimentary Pharmacology & Therapeutics, 2013
- Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2013
- Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti–Tumor Necrosis Factor Therapy for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: A real-life survey in SpainJournal of Crohn's and Colitis, 2010
- Mesalamine in the treatment of mild to moderate active Crohn's ileitis: Results of a randomized, multicenter trialGastroenterology, 1999
- A Comparison of Budesonide and Mesalamine for Active Crohn's DiseaseNew England Journal of Medicine, 1998
- Comparison between high dose 5-aminosalicylic acid and 6-methylprednisolone in active Crohn's ileocolitis. A multicenter randomized double-blind study. German 5-ASA Study Group.1995
- Oral 5-ASA Versus Prednisone in Short Term Treatment of Crohn's Disease: A Multicentre Controlled TrialCanadian Journal of Gastroenterology and Hepatology, 1990